The clinical trial aims to assess the effectiveness of the Objectif Santé Diabète Benin (OSanDiaBé), a culturally tailored medical nutrition therapy (MNT), in enhancing diabetes management and nutrition choices. The investigators hypothesize that participants receiving OSanDiaBé will demonstrate greater improvements in dietary adherence and greater reductions in HbA1c at 6 months compared with those receiving usual care. The investigators further hypothesize that these improvements will be maintained at 12 months following the end of active intervention contact.

This study is a 12-month, parallel-group, randomized controlled trial involving individuals diagnosed with type 2 diabetes. Participants will be randomly assigned in a 1:1 ratio to either (1) usual care (wait-list control group) or (2) nutrition counseling with group-based education (intervention group). The intervention group will receive the OSanDiaBé resource package, which includes a workbook, and an Eating Plan based on the 4-A framework of food security. They will participate in four individual home sessions and eight group sessions in the first six months, with no contact between months six and twelve. The primary outcome will be the change in HbA1c levels, while secondary outcomes will include lipid profile, anthropometric measures, dietary adherence, diabetes self-efficacy, and diabetes-related quality of life. All outcomes will be assessed at baseline, 3, 6, and 12 months.

Inclusion Criteria

• outpatient in one of the participating health centers
• be aged between 40 and 65 years old,
• have a confirmed diagnosis of T2D for a year or longer,
• with uncontrolled diabetes (HbA1c >7%)
• able to read and write in French or a support who read and write in French
• self-identify as Beninese (born in Benin or have parents from Benin),
• willing to commit to the study and able to attend weekly meetings
• have family member support for behavioral change
• suitable for general diet and lifestyle advice (i.e., no complex diet needs; suitability determined by the referring healthcare provider)
• be willing to provide informed consent to participate.

Exclusion criteria

• being pregnant, breastfeeding or planning pregnancy,
• participants with type 1 diabetes
• use of medication that might affect weight loss
• planning to travel before the end of the intervention
• have recent cardiovascular complications (e.g., myocardial infarction, stroke, and congestive heart failure),
• currently involved in a similar nutritional educational program (to avoid contamination bias).
• unable to provide consent (e.g., cognitive impairment).

Data obtained from this study may be shared with qualified researchers who have an academic interest in type 2 diabetes. Any data or samples provided will be coded and will not include any personal health information (PHI). Before sharing the data, the request must receive approval, and all necessary agreements (such as a material transfer agreement) must be in place.

Data requests can be submitted starting 9 months after article publication, and the data will be made accessible for up to 24 months. Extensions will be considered on a case-by-case basis.

Access to trial IPD can be requested by qualified researchers engaging in independent scientific research and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA).